Clinical Trials Browser

Phase 2 × Hematopoietic System--Cancer × Cyclophosphamide × Clear all

NCT03654703 2018-08-31

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Phase 2 Unknown

Hematopoietic System--Cancer